News

Bapineuzumab fails phase III
Enlarge image

BusinessIreland

Bapineuzumab fails phase III

26.07.2012 - Pfizer and Johnson & Johnson report that Bapineuzumab failed the first of four phase III trials.

The monoclonal antibody Bapineuzumab could not outperform a placebo in moderating symptoms of mild-to-moderate Alzheimer's disease. Expectations on an intravenous formulation of the drug to help a group of patients sharing the so called ApoE4 (apolipoprotein E epsilon 4) genotype could not be fulfilled. Pfizer did not release details of the study’s outcome, but a principal investigator in the trial, Reisa Sperling, told The New York Times that "there was absolutely no evidence at all of a clinical benefit of treatment on either of the primary measures." The antibody developed by the Irish company Elan and US company Pfizer is tested in a large-scale Alzheimer's Immunotherapy Program for its suitability for treating the most common form of dementia. Meanwhile Johnson & Johnson joined the team for a total of four clinical trials. 1100 patients participated in the trail, all of them carriers of the ApoE4 risk gene. It is possible that patients without this gene modification could gain more profit from the agent. A second study with this group will start in the following weeks, two others are still ongoing.

Bapineuzumab is the follow up agent of AN1792, a vaccine which also failed. AN1792 successfully stimulated the formation of antibodies against beta amyloid – a protein that can exert toxic effects in the brain and is believed to play a central role in the pathology of Alzheimer's disease – in animal studies. But in 2002, a phase II trial had to be stopped because of safety issues. Aseptic meningoencephalitis and leukoencephalopathy were diagnosed in 6 percent of the participants. Nevertheless, some hints were given that the vaccine achieved an effect. The same effects were expected for Bapineuzumab, of course without the negative consequences.

http://www.european-biotechnology-news.com/news/news/2012-03/bapineuzumab-fails-phase-iii.html

BioeconomyEU

26.08.2015 In its second call for proposals, the Bio-Based Industries Joint Undertaking has earmarked €106m for the research and development of useful bio-based products.

OncologyNorway

25.08.2015 Oslo Cancer Cluster is inaugurating its NOK1bn (€107m) Innovation Park. None other than Norwegian prime minister Erna Solberg officially opened the doors to the research park on August 24th.

LicensingUKSwitzerland

21.08.2015 Novartis Pharma AG has secured all remaining rights to antibody hopeful ofatumumab. Seller GlaxoSmithKline is set to receive up to US$1bn (€919m) for the treatment for MS and other autoimmune indications.

LicensingDenmark

18.08.2015 Danish Novo Nordisk is climbing on the antibody therapeutics bandwagon in a US$500m licensing agreement with antibody-specialist Genmab.

M&ASwitzerland

13.08.2015 Roche is stepping up its commitment in the fight against drug resistant “superbugs” with its takeover of US diagnostics play Geneweave, for up to US$425m.

M&AUK

11.08.2015 Biotech bug controllers Oxitec has been bought by US biotech Intrexon Corporation for $160m (€145m). The Oxford University spin-out specialises in environmentally friendly technology to control pests such as mosquitoes, which cause dengue fever and other diseases.

Research and DevelopmentFranceGermany

07.08.2015 In a deal worth more than €300m, Sanofi has partnered up with German drug discovery and development company Evotec in order to develop beta cell-modulating diabetes therapies.

M&AIrelandUK

05.08.2015 Irish pharma and biotech major Shire wants to be number one in orphan diseases, and is setting out to acquire US-American Baxalta in a US$30bn deal – by any means necessary.

R&DUKSweden

04.08.2015 In a deal worth US$65m upfront, AstraZeneca is again teaming up with long-time partner Isis Pharmaceuticals Inc., this time to discover and develop RNA antisense drugs for cardiovascular, metabolic and renal diseases.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • NEUROVIVE PHARMACEUTICAL AB (S)23.00 SEK25.00%
  • BAVARIAN NORDIC (D)41.03 EUR20.85%
  • TIGENIX (B)1.02 EUR17.24%

FLOP

  • BIOTIE THERAPEUTICS (FI)0.20 EUR-9.09%
  • THROMBOGENICS (B)2.90 EUR-6.15%
  • EVOCUTIS (UK)0.19 GBP-5.00%

TOP

  • KARO BIO (S)38.10 SEK2281.2%
  • TRANSGENE (F)5.08 EUR80.8%
  • TIGENIX (B)1.02 EUR30.8%

FLOP

  • THROMBOGENICS (B)2.90 EUR-42.9%
  • BIONOR PHARMA (N)1.28 NOK-37.6%
  • WILEX (D)2.05 EUR-36.5%

TOP

  • KARO BIO (S)38.10 SEK4546.3%
  • ADOCIA (F)86.70 EUR432.2%
  • VERONA PHARMA (UK)4.92 GBP339.3%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-85.7%
  • BIOTEST (D)19.92 EUR-76.0%
  • NEOVACS (F)0.96 EUR-72.7%

No liability assumed, Date: 29.08.2015